For further details see:
Blueprint Medicines, Mirati, Immunogen gain following Turning Point sale to Bristol Myers (update)For further details see:
Blueprint Medicines, Mirati, Immunogen gain following Turning Point sale to Bristol Myers (update)Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Turning Point Therapeutics Inc. Company Name:
TPTX Stock Symbol:
Market:
New York, United States, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Precision medicine is a new approach to treating and preventing disease that consider...
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...